Last reviewed · How we verify
Trans-catheter embolization — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Trans-catheter embolization (Trans-catheter embolization) — Shenzhen SiBiono GeneTech Co.,Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trans-catheter embolization TARGET | Trans-catheter embolization | Shenzhen SiBiono GeneTech Co.,Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trans-catheter embolization CI watch — RSS
- Trans-catheter embolization CI watch — Atom
- Trans-catheter embolization CI watch — JSON
- Trans-catheter embolization alone — RSS
Cite this brief
Drug Landscape (2026). Trans-catheter embolization — Competitive Intelligence Brief. https://druglandscape.com/ci/trans-catheter-embolization. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing